Trial Profile

A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zoligratinib (Primary)
Indications Advanced breast cancer; Biliary cancer; Head and neck cancer; Mouth neoplasm; Non-small cell lung cancer; Prostate cancer; Solid tumours; Thyroid cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms FUZE
Sponsors Debiopharm

Most Recent Events

22 Feb 2022 Status changed from completed to discontinued.
21 Jan 2022 Status changed from active, no longer recruiting to completed.
16 Jan 2022 This trial has been completed in Croatia , according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com